Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Immunotherapeutic Equipment Supplied In Europe
101 equipment items found
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical ...
by:Fusix Biotech based inMünchen, GERMANY
As multi-mechanistic antitumor agents, oncolytic viruses are emerging to be potent immunotherapeutic treatment options in different tumor indications. Oncoytic viruses specifically replicate in tumor cells due to altered signalling pathways supporting the tumor’s immune esape, leaving open replication advantages for viruses susceptible to intact signaling pathways. ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
OSE’s R&D team and its academic partners have characterized the myeloid checkpoint CLEC-1 (a C-type lectin receptor) as a new therapeutic target in immuno-oncology and identified monoclonal antibody antagonists blocking this novel “Don’t Eat Me” signal. CLEC-1 antagonist monoclonal antibodies have been identified as an innovative cancer immunotherapy that releases the ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets being developed by the Company to fight primary and secondary resistance mechanisms developed by cancers to evade checkpoint inhibitor ...
Manufactured by:IDT Biologika based inDessau-Rosslau, GERMANY
IDT Biologika is a leading viral vector CDMO with an exceptional track record in biologics manufacturing, including expertise with live viral agents. This makes us well-positioned to support the rapid growth in gene therapy and immunotherapeutics markets and the huge demand for transformative viral ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A humanized monoclonal antibody, is an antagonist of the alpha chain of the interleukine-7 receptor, CD127, present on T effector cells, thus down regulating the immune activity. Interleukin-7 (IL-7) is a cytokine that controls the proliferation, apoptosis and activation of CD4 and CD8 effector T-cells in ...
Manufactured by:Dia.Pro Diagnostic Bioprobes s.r.l based inSesto San Giovanni, ITALY
The IgG assay is intended for testing: (a) health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing anti Spike IgG; (b) normal population for epidemiology studies on presence of potential “protective” IgG to COVID-19 Spike antigens; (c) PCR-negative infected individuals, successfully recovered from infection, to ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
a monoclonal antibody fragment and CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal. The net effect of CD28 antagonism is down regulating effector T-cells while promoting T-Reg activity. The CD28/CTLA-4 pathway controls both T-cell activation and regulatory T-cell down regulation. CD28 receptor is expressed on the surface of the majority of ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Most anti-inflammatory agents act using a mechanism that blocks pro-inflammation pathways. In contrast, OSE Immunotherapeutics is developing OSE-230 as a first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to complete the inflammation program and restore tissue ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
In recent years, immunotherapies have driven significant clinical progress and increased hopes for patients suffering from various types of cancer. The tumor microenvironment (TME), in particular the presence and immune-status of myeloid derived suppressor cells (MDSC), tumor-associated macrophages (TAM) as well as dendritic cells, has been closely linked to tumor activity and responsiveness to ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to identify vaccine ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
Liquid, ready-to-use subcutaneous immunoglobulin (SCIg). ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
Liquid, ready-to-use subcutaneous immunoglobulin ...
Manufactured by:Anaveon AG based inBasel, SWITZERLAND
The culmination of our research is ANV419, which is in clinical development. It is a rationally engineered fusion protein that is a stable, antibody-like molecule. ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s ...
Manufactured by:HAL Allergy Group based inLeiden, NETHERLANDS
HAL Allergy offers allergen drops that can be administered by applying a few drops under the tongue (sublingual immunotherapy). Sublingual products are manufactured from standardized allergen extracts formulated in glycerol. Glycerol improves the dosing of the product by enhancing the stickiness in the mouth, and is a stabilizer of the allergen ...
Manufactured by:AJ Vaccines A/S based inKøbenhavn, DENMARK
VesiCulture (BCG Culture) For the treatment of Bladder ...